Chiron rejects Novartis bid

CHIR rejected as "inadequate" an offer from Novartis (NVS; SWX:NOVN) to acquire the 58% of CHIR it does not already own for $4.5 billion, or $40 per share, in cash (see BioCentury Extra, Thursday Se...